23 Jul, 2026
According to Straits Research, the global gout therapeutics market size was valued at $3.05 billion in 2025 and is projected to grow from $3.24 billion in 2026 to $5.40 billion by 2034, registering a CAGR of 6.57% during the forecast period 2026–2034.
The global gout therapeutics market is experiencing steady growth, primarily driven by the rising prevalence of gout worldwide, closely linked to increasing cases of obesity, hypertension, diabetes, and aging populations. Changes in dietary habits, higher alcohol consumption, and sedentary lifestyles have contributed to a growing patient pool. Additionally, improved disease awareness and better diagnostic rates have led to earlier initiation of treatment, increasing long-term demand for urate lowering therapies and anti-inflammatory drugs. Furthermore, the introduction of advanced treatment options, including biologics for chronic and refractory gout, has strengthened physician confidence and expanded treatment adoption across hospital and specialty care settings.
Despite this, the market faces a key restraint in the form of high treatment costs associated with advanced and biologic gout therapies. This limits accessibility for patients and places a financial burden on healthcare systems. Reimbursement challenges and strict payer approval criteria further restrict widespread uptake of premium therapies, slowing market penetration in cost-sensitive regions.
On the other hand, a major opportunity lies in the development of novel targeted and long-acting gout therapies, including urate lowering agents and combination treatments. Ongoing research focused on improving efficacy, reducing flare frequency, and enhancing patient compliance is expected to transform disease management. Moreover, expanding healthcare infrastructure and increasing clinical research activity in emerging markets provide manufacturers with opportunities to reach underserved populations and strengthen their global presence.
sales@straitsresearch.com